Abstract
To investigate the effects of baseline testosterone on testosterone control and prostate-specific antigen (PSA) suppression using data from a phase III trial (CS21) comparing degarelix and leuprolide in prostate cancer.
| Original language | English |
|---|---|
| Journal | Urology |
| Volume | 80 |
| Issue number | 1 |
| Pages (from-to) | 174-80 |
| Number of pages | 7 |
| ISSN | 0090-4295 |
| DOIs | |
| Publication status | Published - 2012 |
Keywords
- Aged
- Antineoplastic Agents, Hormonal
- Gonadotropin-Releasing Hormone
- Humans
- Leuprolide
- Male
- Oligopeptides
- Prostatic Neoplasms
- Testosterone
Fingerprint
Dive into the research topics of 'The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS